(This commentary was not written by CRD, but by the authors of the DH Register.)
1) Side effects of therapy are discussed but not included. 2) The costing methodology based on macro usage of health resources is of uncertain accuracy. 3) The paper makes a deliberately optimistic appraisal of therapy, in addition the type of model used is likely to be inaccurate, assuming a constant cost/benefit stream.